Management of advanced bladder cancer in patients with impaired renal function

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 931-939

  Bournakis, Evangelos ^a   Dimopoulos, Meletios A ^a   Bamias, Aristotle ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

advanced bladder cancer; cisplatin ineligible; impaired renal failure; platinum based; platinum free; transitional cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; LAPATINIB; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ANEMIA; BLADDER CANCER; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; METABOLIC ACIDOSIS; METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; VOMITING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; RENAL INSUFFICIENCY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 79959773808     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.197     Document Type: Review

References (74)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 277-300 (2010
2. American Cancer Society. Cancer facts and figures 2010. American Cancer Society, GA, USA (2010
3. Jemal A, Murray T, Ward E et al. Cancer statistics. CA Cancer J. Clin. 55, 10 (2005
4. Pelucchi C, Bosetti C, Negri E et al. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 3, 327 (2006
5. NCCN. Bladder cancer treatment guidelines 2005. National Comprehensive Cancer Network (2005
6. Von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005 (Pubitemid 46224062)
7. Loehrer PJ, Einhorn LH, Elson PJ et al. A randomised comparison of cisplatin alone or in combinations with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study. J. Clin. Oncol. 10, 1066-1073 (1992
8. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours. J. Clin. Oncol. 8, 1050-1055 (1990 (Pubitemid 20200193)
9. Bamias A, Aravantinos G, Deliveliotis CH et al. Docetaxel and cisplatin with granulocyte-colony stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomised, Phase III study conducted by the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 22, 220-228 (2004 (Pubitemid 41095085)
10. Sternberg CN, de Mulder PH, Lund B et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus the classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J. Clin. Oncol. 19, 2638-2646 (2001 (Pubitemid 32441368)
11. Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomised, multinational, multicenter, Phase III study. J. Clin. Oncol. 17, 3068-3077 (2000
12. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17, 3173-3181 (1999 (Pubitemid 29470648)
13. Vaughn DJ. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium. Cancer Treat. Rev. 34, 328-338 (2008
14. Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506-513 (2006 (Pubitemid 44107210)
15. Vercelli M, Quaglia A, Parodi S, Crosignani P. Cancer prevalence in the elderly. ITAPREVAL Working Group. Tumori 85, 391 (1999
16. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol. Rep. 10, 1663 (2003
17. Litterst CL, Torres IJ, Guarino AM et al. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP (IIJ. Clin. Hematol. Oncol. 7, 169 (1977
18. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 25, 753 (1984
19. Dobyan DC, Levi J, Jacobs C et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J. Pharmacol. Exp. Ther. 213, 551 (1980
20. Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol. Dial. Transplant. 7, 1 (1992
21. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am. J. Physiol. 249, F490 (1985
22. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110, 835 (2002
23. Ramesh G, Reeves WB. P38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am. J. Physiol. Renal. Physiol. 289, F166 (2005
24. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966-1972 (1997). (Pubitemid 27479792)
25. Carteni G, Dogliotti L, Crucitta A et al. Phase II randomized trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1543
26. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized Phase II study. Cancer 77, 344-351 (1996
27. Carteni G, Dogliotti L, Crucitta A et al. Phase II randomized trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1543
28. Carles J, Suarez C, Mesia C et al. Feasibility study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. Clin. Transl. Oncol. 8(10), 755-757 (2006
29. Hussain SA, Stocken D, Riley P et al. A Phase I/II study of gemcitabine and fractionated cisplatin in an outpatients setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br. J. Cancer 91, 844-849 (2004 (Pubitemid 39273773)
30. Bamias A, Lainakis G, Kastritis E et al. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. Oncology 73(5-6), 290-297 (2007 (Pubitemid 351862018)
31. Linardou H, Aravantinos G, Efstathiou E et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Cooperative Oncology Group. Urology 64, 479-484 (2004 (Pubitemid 39200741)
32. Bellmunt J, de WR, Albanell J et al. A feasibility study of carboplatin with fixed dose of gemcitabine in unfit patients with advanced bladder cancer. Eur. J. Cancer 37, 2212-2215 (2001 (Pubitemid 33001291)
33. Carles J, Nogue M, Domenech M et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59, 24-27 (2000 (Pubitemid 30435831)
34. De Santis M, Bellmunt J, Mead G et al. Randomized Phase II/III trial assessing gemcitabine/carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer 'unfit' for cisplatin-based chemotherapy: Phase II - results of EORTC study 30986. J. Clin. Oncol. 27(33), 5634-5639 (2009
35. Helke C, May M, Hoschke B. Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function. Aktuelle Urol. 37(5), 363-368 (2006 (Pubitemid 44670551)
36. Roth, BJ, Dreicer, R, Einhorn, LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12, 2264 (1994
37. Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 16, 255-260 (1998 (Pubitemid 28041606)
38. Small EJ, Lew D, Redman BG et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 18, 2537-2544 (2000 (Pubitemid 30432519)
39. Vaughn DJ, Manola J, Dreicher R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95, 1022-1027 (2002 (Pubitemid 34925352)
40. Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19, 2527-2533 (2001 (Pubitemid 32391224)
41. Galsky MD, Iasonos A et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109, 549-555 (2007 (Pubitemid 46190963)
42. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70, 163-169 (1986 (Pubitemid 16140378)
43. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drur Screen panel. Biochem. Pharmacol. 52(12), 1855-1865 (1996 (Pubitemid 26419675)
44. Carles J, Esteban E, Climent M et al. Gemcitabine and oxaliplatin combination: a multicenter Phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann. Oncol. 18, 1359-1362 (2007 (Pubitemid 47305010)
45. de Wit R, Kruit WH, Stoter G et al. Docetaxel: an active agent in metastatic urothelial cancer; results of a Phase II study in non-chemotherapy-pretreated patients. Br. J. Cancer 78, 1342-1345 (1998 (Pubitemid 28495247)
46. Roth BJ, Dreicher R, Einhorn LH et al. significant activity of paclitaxel in advanced TCC of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12, 2264-2270 (1994 (Pubitemid 24346693)
47. Yang MH, Yen CC, Chang YH et al. Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency. Jpn J. Clin. Oncol. 30, 547-552 (2000
48. Dimopoulos MA, Deliveliotis C, Moulopoulos LA et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 52, 56-60 (1998 (Pubitemid 28317930)
49. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 20(4), 937-940 (2002 (Pubitemid 34141835)
50. Ricci S, Galli L, Chioni A et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 95, 1444-1450 (2002
51. Turkolmez K, Beduk Y, Baltaci S et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who failed cisplatin-based chemotherapy. Eur. Urol. 44, 682-686 (2003 (Pubitemid 37542926)
52. Kaufman DS, Carducci MA et al. A multi-institutional Phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol. Oncol. 22, 393-397 (2004
53. Gitlitz BJ, Baker C, Chapman Y et al. A Phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98, 1863-1869 (2003 (Pubitemid 37310229)
54. Kastritis E, Dimopoulos MA, Antoniou N et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res. 26(5B), 3865-3869 (2006). (Pubitemid 44701473)
55. Dreicer, R, Li, H, Stein, MN et al. Phase II trial of sorafenib in advanced carcinoma of the urothelium (E1804): a trial of the Eastern Cooperative Oncology Group (abstractJ. Clin. Oncol. 26, 270 (2008
56. Nishiyama, H, Habuchi, T, Watanabe, J et al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur. Urol. 45, 176 (2004
57. Culine S, Theodore C, De Santis M et al. A Phase II study of vinflumine in bladder cancer patients progressing after first-line platinum containing regimen. Br. J. Cancer 94, 1395-1401 (2006 (Pubitemid 43772272)
58. Vaughn DJ, Srinivas S, Stadler WM et al. Vinflumine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large Phase II study. Cancer 115(18), 4110-4117 (2009
59. Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr. Opin. Urol. 19(5), 533-539 (2009
60. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflumine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27(27), 4454-4461 (2009
61. Sweeney CJ, Roth BJ et al. Phase II study of pemetrexed for second line treatment of TCC of the urothelium. J. Clin. Oncol. 24, 3451-3457 (2006 (Pubitemid 46638903)
62. Galsky MD, Mironov S, Iasonos A et al. Phase II study of pemetrexed as second line therapy in patients with metastatic urothelial carcinoma. Invest. New Drug 25, 265-270 (2007 (Pubitemid 46774696)
63. Limas C. state of the urothelium with benign and atypical changes. Correlation with transferrin and epidermal growth factor receptors and blood group antigens. J. Pathol. 171, 39 (1993
64. Daher A, de Boer WI, El-Marjou A et al. Epidermal growth factor receptor regulates normal urothelial regeneration. Lab. Invest. 83, 1333 (2003
65. Neal DE, Marsh C, Bennett MK et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1, 366 (1985
66. Cheng, J, Huang, H, Zhang, ZT et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 62, 4157 (2002
67. Perrotte, P, Matsumoto, T, Inoue, K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257 (1999
68. Hussain MH, Mac Vicar GR, Ptrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter Phase II National Cancer Institute trial. J. Clin. Oncol. 25, 2218-2224 (2007 (Pubitemid 46954646)
69. Wülfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115(13), 2881-2890 (2009
70. Dreicer R, Li H, Stein MN et al. Phase II trial of sorafenib in advanced carcinoma of the urothelium (E1804): a trial of the Eastern Cooperative Oncology Group (abstractJ. Clin. Oncol. 26, 270 (2008
71. Sridhar SS. A Phase II study of first-line sorafenib (BAY 43-9006) in advanced or metastatic urothelial cancer. A trial of the PMH Phase II Consortium. Presented at: Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2007 (Abstract
72. Bamias A, Kyriakou F, Chorti M et al. Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ β-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a Hellenic Cooperative Oncology Group (HECOG) study. Anticancer Res. 28, 2479-2486 (2008
73. Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol. 28(8), 1373-1379 (2010
74. Ehdaie B, Smith SC, Theodorescu D. Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. Can. Urol. Assoc. J. 3(6 Suppl. 4), S232-S236 (2009).